ABOS (Acumen Pharmaceuticals) 3-1 Month Momentum %: -9.31% (As of Jul. 12, 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.63
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals 3-1 Month Momentum %?

Acumen Pharmaceuticals ABOS -2.59% 34 3-1 Month Momentum % is -9.31% as of Jul. 12, 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Acumen Pharmaceuticals ranks better than 54.28% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-12), Acumen Pharmaceuticals's 3-1 Month Momentum % is -9.31%.

The industry rank for Acumen Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

ABOS's 3-1 Month Momentum % is ranked better than
54.28% of 1389 companies
in the Biotechnology industry
Industry Median: -11.38 vs ABOS: -9.31

Acumen Pharmaceuticals  (NAS:ABOS) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Acumen Pharmaceuticals 3-1 Month Momentum % Related Terms

ABOS vs YDES, PYXS, CRBU: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Acumen Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's 3-1 Month Momentum % falls into.


ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals  (NAS:ABOS) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -9.31% mean?
Acumen Pharmaceuticals (ABOS) has a 3-1 Month Momentum % of -9.31% as of Jul. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Acumen Pharmaceuticals and its competitors. According to the industry distribution chart, Acumen Pharmaceuticals ranks #635 out of 1389 companies in the Biotechnology industry, placing it in the top 45.7%.
Is Acumen Pharmaceuticals' 3-1 Month Momentum % too high?
Acumen Pharmaceuticals' current 3-1 Month Momentum % is -9.31%. Based on the distribution chart, Acumen Pharmaceuticals ranks #635 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' 3-1 Month Momentum % compare to YDES and PYXS?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #635 out of 1389 companies for 3-1 Month Momentum %. This puts Acumen Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current 3-1 Month Momentum % is -9.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current 3-1 Month Momentum % of -9.31%. The current 3-1 Month Momentum % is -9.31%. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current 3-1 Month Momentum % is -9.31% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price